These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 12183630)
1. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Huizinga EG; Tsuji S; Romijn RA; Schiphorst ME; de Groot PG; Sixma JJ; Gros P Science; 2002 Aug; 297(5584):1176-9. PubMed ID: 12183630 [TBL] [Abstract][Full Text] [Related]
3. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX. Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727 [TBL] [Abstract][Full Text] [Related]
4. Role of the leucine-rich domain of platelet GPIbalpha in correct post-translational processing--the Nancy I Bernard-Soulier mutation expressed on CHO cells. Ulsemer P; Lanza F; Baas MJ; Schwartz A; Ravanat C; Briquel ME; Cranmer S; Jackson S; Cazenave JP; de la Salle C Thromb Haemost; 2000 Jul; 84(1):104-11. PubMed ID: 10928479 [TBL] [Abstract][Full Text] [Related]
5. Molecular modeling of the seven tandem leucine-rich repeats within the ligand-binding region of platelet glycoprotein Ib alpha. Whisstock JC; Shen Y; López JA; Andrews RK; Berndt MC Thromb Haemost; 2002 Feb; 87(2):329-33. PubMed ID: 11858495 [TBL] [Abstract][Full Text] [Related]
6. Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregation. Dumas JJ; Kumar R; Seehra J; Somers WS; Mosyak L Science; 2003 Jul; 301(5630):222-6. PubMed ID: 12855811 [TBL] [Abstract][Full Text] [Related]
7. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Fukuda K; Doggett T; Laurenzi IJ; Liddington RC; Diacovo TG Nat Struct Mol Biol; 2005 Feb; 12(2):152-9. PubMed ID: 15665869 [TBL] [Abstract][Full Text] [Related]
8. Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity. Li CQ; Ye P; Cao Zf ; Wang H; Lu L; Nicastro P; Wood E; Robert JJ; Ouwehand WH; Hill F; López JA; Wardell MR Protein Expr Purif; 2001 Jul; 22(2):200-10. PubMed ID: 11437595 [TBL] [Abstract][Full Text] [Related]
9. Identification of peptide antagonists to glycoprotein Ibalpha that selectively inhibit von Willebrand factor dependent platelet aggregation. Benard SA; Smith TM; Cunningham K; Jacob J; DeSilva T; Lin L; Shaw GD; Kriz R; Kelleher KS Biochemistry; 2008 Apr; 47(16):4674-82. PubMed ID: 18363340 [TBL] [Abstract][Full Text] [Related]
10. Specific electrostatic interactions between charged amino acid residues regulate binding of von Willebrand factor to blood platelets. Interlandi G; Yakovenko O; Tu AY; Harris J; Le J; Chen J; López JA; Thomas WE J Biol Chem; 2017 Nov; 292(45):18608-18617. PubMed ID: 28924049 [TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic truncation of glycoprotein Ib alpha weakens its interaction with von Willebrand factor and impairs cell adhesion. Schade AJ; Arya M; Gao S; Diz-Küçükkaya R; Anvari B; McIntire LV; López JA; Dong JF Biochemistry; 2003 Feb; 42(7):2245-51. PubMed ID: 12590614 [TBL] [Abstract][Full Text] [Related]
12. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. Martin C; Morales LD; Cruz MA J Thromb Haemost; 2007 Jul; 5(7):1363-70. PubMed ID: 17389010 [TBL] [Abstract][Full Text] [Related]
13. Force-induced on-rate switching and modulation by mutations in gain-of-function von Willebrand diseases. Kim J; Hudson NE; Springer TA Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4648-53. PubMed ID: 25810255 [TBL] [Abstract][Full Text] [Related]
14. Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations. Rastegar-Lari G; Ajzenberg N; Ribba AS; Vereycken-Holler V; Legendre P; Villoutreix B; Meyer D; Baruch D Thromb Haemost; 2001 Dec; 86(6):1459-65. PubMed ID: 11776314 [TBL] [Abstract][Full Text] [Related]
15. Structure-function relationship of the A1 domain of von Willebrand factor. Girma JP; Ribba AS; Meyer D Thromb Haemost; 1995 Jul; 74(1):156-60. PubMed ID: 8578449 [TBL] [Abstract][Full Text] [Related]
16. A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation. Hauert J; Fernandez-Carneado J; Michielin O; Mathieu S; Grell D; Schapira M; Spertini O; Mutter M; Tuchscherer G; Kovacsovics T Chembiochem; 2004 Jun; 5(6):856-64. PubMed ID: 15174170 [TBL] [Abstract][Full Text] [Related]
17. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. Yago T; Lou J; Wu T; Yang J; Miner JJ; Coburn L; López JA; Cruz MA; Dong JF; McIntire LV; McEver RP; Zhu C J Clin Invest; 2008 Sep; 118(9):3195-207. PubMed ID: 18725999 [TBL] [Abstract][Full Text] [Related]
18. The N-terminal flanking region of the A1 domain regulates the force-dependent binding of von Willebrand factor to platelet glycoprotein Ibα. Ju L; Dong JF; Cruz MA; Zhu C J Biol Chem; 2013 Nov; 288(45):32289-32301. PubMed ID: 24062306 [TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. Dumas JJ; Kumar R; McDonagh T; Sullivan F; Stahl ML; Somers WS; Mosyak L J Biol Chem; 2004 May; 279(22):23327-34. PubMed ID: 15039442 [TBL] [Abstract][Full Text] [Related]
20. Role of glycoprotein Ibalpha mobility in platelet function. van der Wal DE; Verhoef S; Schutgens RE; Peters M; Wu Y; Akkerman JW Thromb Haemost; 2010 May; 103(5):1033-43. PubMed ID: 20216992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]